A syndicate led by Forbion Capital Partners of the Netherlands has secured $25 million in Series D financing for Argos Therapeutics Inc of the US to support a Phase 3 study of the company’s immunotherapy for metastatic renal cell carcinoma. The trial is being run under an SPA.
